Article
Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Journal for immunotherapy of cancer - 1 Jun 2022
Wang Zhenghang, Zhang Qi, Qi Changsong, Bai Yuezong, Zhao Feilong, Chen Hui, Li Zhongwu, Wang Xicheng, Chen Mifen, Gong Jifang, Peng Zhi, Zhang Xiaotian, Cai Jinping, Chen Shiqing, Zhao Xiaochen, Shen Lin, Li Jian
Abstract excerpt
BACKGROUND: Gastrointestinal (GI) cancer is the second most common cancer type with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype that is expected to respond to immune-checkpoint inhibitors (ICIs). However, approximately half of the patients with dMMR/MSI-H GI cancer derive no benefit from ICIs. We sought to identify the predictors of primary resistance to ICIs in dMMR/MSI-H...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.